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SUMMARY
 
HIV-associated immune reconstitution disease (IRD) is the
clinical presentation or deterioration of opportunistic infections
that results from enhancement of pathogen-specific immune
responses among patients responding to antiretroviral treatment
(ART). The vast majority of reported cases of IRD have been
associated with mycobacterial, chronic viral and invasive fungal
infections; such cases result from dysregulated augmentation of
cell-mediated type 1 cytokine-secreting host immune responses.
However, the spectrum of infections now recognized as associated
with IRD is expanding and includes a number of parasitic
infections, which may be mediated by different immunopatholog-
ical mechanisms. These include leishmaniasis (visceral, cutaneous,
mucosal and post kala azar dermal leishmaniasis), schisto-
somiasis and strongyloidiasis. Since the major burden of HIV
lies in resource-limited countries where access to ART is now
rapidly expanding, increased awareness and knowledge of these
phenomena is important. Here we review the clinical spectrum
and pathogenesis of IRD associated with parasitic infections.
 
Keywords
 
antiretroviral treatment, HAART, HIV, immune
reconstitution inflammatory syndrome, immune reconstitution,
immune restoration, IRIS, parasitic infection, tropical infection 
 
INTRODUCTION
 
HIV-associated morbidity and mortality has dramatically
decreased in many high-income countries since the advent of
antiretroviral treatment (ART) in the mid 1990s (1–3). Robust
suppression of viral replication by ART permits both quan-
titative and functional reconstitution of the immune system
(4–6). As a result, primary and secondary prophylaxis for
many opportunistic infections that occur among those with
advanced immunodeficiency can often be discontinued (7).
However, the initial rapid phase of immune recovery may
also directly result in adverse clinical phenomena. Previously
subclinical infections may be ‘unmasked’ or pre-existing
partially treated opportunistic infections may clinically dete-
riorate (8–10). Such phenomena are believed to arise from a
dysregulated augmentation of the host inflammatory response
to these infections. Various terms have been used to refer to
this, including ‘immune reconstitution syndrome’, ‘immune
restoration disease’, and the ‘immune reconstitution
inflammatory syndrome’ (familiarly abbreviated to ‘IRIS’).
In this review we have used the term ‘immune reconstitution
disease’ (IRD).
IRD is not a new phenomenon, but has long been recog-
nized as a complication occurring among patients with severe
immunosuppression in whom immune function is rapidly
restored. Thus, for example, IRD may occur following with-
drawal or rapid dosage reduction of corticosteroid treatment
and among patients in whom the blood neutrophil count
recovers following cytotoxic chemotherapy or bone marrow
transplantation (11). The pathogens involved in IRD reflect
the spectrum of opportunistic infections associated with the
specific form of  immunosuppression. For example, IRD
following recovery from neutropenia is typically associated
with fungal and pyogenic infections (11).
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The vast majority of cases of IRD associated with ART
have been reported from high-income countries and have been
associated with a wide range of non-parasitic opportunistic
infections, including: (a) bacteria (
 
Mycobacterium tuberculosis
 
,
 
Mycobacterium avium
 
 complex and other non-tuberculous
mycobacteria); (b) viruses (cytomegalovirus, varicella zoster
virus, herpes simplex virus, human herpes virus-8, hepatitis
B and C and JC virus); and (c) fungi (
 
Pneumocystis jirovecii
 
,
 
Cryptococcus neoformans and Histoplasma
 
 spp.) (8–10).
However, the spectrum of infections recognized to be associ-
ated with IRD continues to increase and case reports now
describe IRD associated with some parasitic infections
(
 
vide infra
 
).
The majority of people with HIV/AIDS live in resource-
limited countries and in June 2005 WHO estimated that 6·5
million people living in such countries were in urgent need
of ART (12). Despite formidable logistical challenges, access
to ART is now expanding. However, patients in resource-
limited settings typically enter ART programmes with advanced
symptomatic disease and very low blood CD4 cell counts
(13,14). This predisposes them to high rates of both clinical
and subclinical opportunistic infections that may potentially
be associated with IRD. To date, IRD associated with
tuberculosis and cryptococcocal meningitis is reported to be
associated with the greatest burden of morbidity and mortality
in sub-Saharan Africa (13,15). However, the prevalence of
chronic parasitic infections is very high in these populations
and yet very little is known about whether these infections
may either be associated with IRD or may perhaps modulate
immune responses involved in IRD associated with other
pathogens. In this paper we review what is currently known
about the clinical manifestations and pathogenesis of IRD
associated with parasitic infections.
 
DEFINITION OF IRD
 
IRD can be defined as the clinical presentation or deteriora-
tion of opportunistic infections that results from enhancement
of pathogen-specific immune responses among patients
responding to ART. However, diagnosis in practice is not
straightforward, being one of clinical judgement based on
various lines of indirect evidence. These may include: (a) the
clinical manifestation or pattern of progression of an oppor-
tunistic infection that is unusual; (b) a temporal relationship
with ART initiation; (c) exclusion of alternative explanations;
(d) demonstrated efficacy of ART (e.g. reduction in viral load
or rise in CD4 cell count; (e) evidence of  improved CD4
cell function (e.g. development of a positive tuberculin skin
test); and (f ) histopathology consistent with the diagnosis.
Competing explanations for these clinical manifestations
that should be excluded are the occurrence of opportunistic
infections as a result of residual immunodeficiency and
inadequate treatment of an opportunistic infection, including
that resulting from drug resistance.
 
IMMUNOLOGICAL EFFECTS OF ART
 
Successful ART is associated with a rapid (> 90%) reduction
in plasma viral load within the first weeks of ART. The most
characteristic immunological feature of HIV infection is deple-
tion of CD4 T cell numbers, and restoration of the CD4 cell
subset during ART appears to occur in two principal phases.
The initial rapid phase of CD4 cell recovery can usually be
detected within the first 1–2 weeks of starting treatment and
extends over 2–3 months (4,5). Data suggest that this phase
largely represents a redistribution of activated CD4
 
+
 
CD45RO
 
+
 
memory cells previously sequestered in lymphoid tissue and
a reduction in apoptotic cell death (4,5,16,17). Those with the
greatest pretreatment viral loads and CD4 decline have the
greatest rates of phase 1 CD4 cell count recovery (18–21). A
slower second phase of  CD4 cell expansion persists for 1–
2 years with variable smaller increments occurring thereafter.
This second thymus-dependent phase is associated with
expansion of naïve CD45RA
 
+
 
CD62L
 
+
 
 cells (4,22).
The increase in circulating CD4 cell numbers is also asso-
ciated with an improvement in effector function, the extent
of  which is directly related to the degree of  viral load
suppression and the CD4 cell counts in the longer term (6).
IL-2-mediated T lymphocyte proliferative responses to recall
antigens are restored (23,24). A switch from type 2 to type
1 cytokine profiles in T lymphocyte stimulation assays and
in tissues is detectable early in treatment, with increases in
IFN-
 
γ
 
 and IL-2 production in response to antigen (25,26).
There is diversification of the pathogen-specific T cell receptor
repertoire (27,28) and delayed-type hypersensitivity responses
to antigens assessed by skin testing are restored (24,29).
Although HIV is principally characterized by CD4 cell
depletion, functional deficits in other cells of the innate and
acquired immune systems also occur. However, the literature
concerning effects of ART on other cell types is much less
comprehensive than that concerning CD4 cell reconstitution.
Moreover, many of these effects are CD4 cell-dependent, so that
attributing ART-induced improvements in immune function
to either CD4 cells or to other cell types is difficult.
Decreased macrophage function, including impaired
chemotaxis, binding of microorganisms, phagocytosis, anti-
gen processing, microbicidal activity and capacity to secrete
interleukin-12 is recognized (30–34). However, data on the
impact of ART on these functions are lacking. Dendritic
cells (DC) in their role as antigen-presenting cells exert a
substantial influence on the phenotype of the subsequent
acquired immune response. Both plasmacytoid (pDC) and
myeloid (mDC) subsets are reduced in numbers in HIV
infection. During ART there is evidence that the defect in
 © 2006 The Authors 
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pDC is only partially reversible (35,36), whereas the mDC
subset appears better reconstituted by ART (35–37). This
differential recovery is of interest when considering IRD
because the mDC subset is responsible for polarizing acquired
response towards type 1 responses. Reduced CD4
 
+
 
 T cell
counts are also associated with decreased circulating CD3
 
–
 
/
CD16
 
+
 
/CD56
 
+
 
 NK cells (38), however, ART does not appear
to be associated with an increase in NK cell function (38–41).
CD8 activation (as determined by co-expression of CD38
and HLA-DR) decreases during ART (4,16,22), probably
reflecting to a large extent the reduction in HIV-specific CD8
response that accompanies the reduction in antigen load (42).
However, CD8-mediated responses to CMV, for example,
improve in the context of an expanding T cell repertoire (28),
an effect which appears CD4 cell dependent (43).
The apparent marked dysregulation of the immune
response that characterizes IRD suggests that T regulatory
cell function may be an important factor in the development
of IRD. An inhibitory effect on the ability of DC to mature
from peripheral monocytes has been attributed to the presence
of HIV-induced CD4
 
+
 
 CD25
 
+
 
 IL-10-secreting T regulatory
cells (44). In addition regulatory T cells are present at higher
frequency in the tonsillar tissue of  untreated patients than
in tissue from those receiving ART (45). It is possible that
decreased T regulatory cell function during ART may enable
mDC to polarize the acquired immune response towards
type 1, thereby favouring development of IRD.
HIV infection is associated with polyclonal B cell activa-
tion and defective specific antibody responses (46) and ART
is associated with a reduction in risk of serious bacterial
infections (e.g. pneumococcal disease) in which immunity is
antibody-dependent (47). Furthermore, ART improves the
antibody response following vaccination or revaccination,
although restoration is not always complete (48,49). There
is very little information, however, about the effect of ART
on eosinophil numbers and on either specific or total IgE
responses that may be relevant to development of IRD in
association with helminth infections.
 
IMMUNOLOGICAL MECHANISMS OF IRD
 
IRD is most likely to develop in association with those infec-
tions for which immune responses are markedly suppressed
by HIV and rapidly restored during ART. It occurs most frequ-
ently among patients with nadir CD4 cell counts < 50 cells/
 
µ
 
L (8,10) who frequently have either subclinical infections or
suppressed responses to clinical disease and yet also retain
capacity for rapid increments in immune function (21). IRD
results from exaggerated host inflammatory responses to
soluble antigen, live organisms (in the case of subclinical or
partially treated infections) or dead organisms (in the case
of treated infections) (8,10,15). It is also recognized that
antigen may persist on DC for long periods, a phenomenon
recently demonstrated 
 
in vivo
 
 for HIV antigen despite success-
ful ART (50). When viable organisms are present, it may be
difficult to distinguish between IRD and active opportunistic
infection, including that resulting from drug resistance. Whilst
antigen concentration is likely to influence the risk and
severity of IRD, this has not been formally studied.
The vast majority of cases of IRD develop in the first
3 months of ART (8,10), corresponding to the first phase of
immune reconstitution in which there is a very rapid increase
in both the number of circulating of CD45RO
 
+
 
 memory cells
as well as CD4 cell function (4). The extent of sequestration
of activated CD45RO
 
+
 
 memory cells in lymphoid tissue may
be directly related to the HIV load, which would explain
why those with the greatest pretreatment viral loads have
the greatest phase 1 rates of CD4 cell recovery during ART
(18,19) and the greatest risk of IRD (51,52). Recirculation
of this previously sequestered cell population may provide the
opportunity for relevant pathogen-specific cells to gain access
to sites of infection and engage in the host inflammatory
response to foreign antigen. IRD can develop within the first
1–2 weeks of ART even prior to any detectable increase in
circulating CD4 cell numbers, and this is likely to reflect
rapid improvements in immune function.
Most cases of IRD are associated with chronic bacterial
infections, viral infections and deep fungal infections, which
typically trigger immunopathology via cell-mediated T-helper
type 1 (T
 
H
 
1) cytokine-secreting immune responses (8,10,53).
Much of our knowledge about the mechanisms of IRD comes
from study of cases of mycobacterial IRD (10). Development
of IRD coincides with restoration of T lymphocyte prolifer-
ative responses, IFN-
 
γ
 
 secretion and cell-mediated immune
responses to mycobacteria, leading to restoration of delayed
type hypersensitivity skin test responses to mycobacterial
antigens (29,54,55). These processes are associated with expan-
sion in the number of antigen-specific T cells during IRD
(53). Reports of hypercalcaemia (resulting from autologous
production of 1,25 dihydroxycholecalceriferol) as a manifes-
tation of mycobacterium-associated and cryptococcal IRD
also provide evidence of restoration of the physiological
function of granulomas (56,57). As might be expected, IRD
associated with viral infections, such as cytomegalovirus, JC
virus, varicella-zoster virus and hepatitis C virus, is associated
with restoration of CD8 T cell responses (58–61). However,
data regarding mechanisms of IRD associated with other
types of opportunistic infections are lacking.
What determines whether a patient develops immune
responses that effectively clear infection vs. responses that lead
to the development of florid immunopathology is not clear.
It is perhaps the rapidity with which cell-mediated immune
responses are restored and a lack of compensating immuno-
regulatory mechanisms may lead to the uncontrolled
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tissue-damaging responses that characterize IRD. In this
respect, it has been speculated that some patients may have
a genetically determined immunological predisposition to
development of IRD (62). It is hypothesized that polymor-
phisms in cytokine genes may influence the rate of clearance
of opportunistic pathogens or may cause dysregulation of the
inflammatory response. Association of such polymorphisms
with development of IRD has been described in small groups
of patients developing IRD associated with a range of organ-
isms (62). However, whether mechanistic relationships exist
has yet to be demonstrated.
 
IRD ASSOCIATED WITH PARASITIC 
INFECTIONS
 
The number of  reports of  IRD associated with parasitic
diseases is small but increasing (Table 1) and most have been
among immigrants to developed countries. Several reasons
may underlie this paucity of data. The association of parasitic
infections with IRD may be infrequent or may typically be
mild or non-specific, leading to lack of recognition. Indeed,
many parasitic infections such as schistosomiasis, trypano-
somiasis and filariasis have complex systems of  immune
evasion, permitting these organisms to exist with little or no
host inflammatory response (63). Furthermore, most parasitic
diseases induce T-helper type 2 cytokine-secreting immune
responses, mediated by antibody production and eosinophils.
While such responses may be augmented by restoration of
appropriate T-helper cell function during ART, the resulting
effects on acute inflammatory processes are perhaps less likely
to be clinically apparent compared to those resulting from
augmentation of type 1 immune responses. Other reasons for
the lack of reported cases of IRD associated with parasitic
infections may include lack of  awareness of  health care
personnel or lack of facilities in resource-limited settings to
establish diagnoses. However, as clinical awareness of the
spectrum of IRD increases and experience with ART grows
in resource-limited countries, cases may be recognized more
frequently.
 
Leishmaniasis
 
Visceral disease (VL) is the clinical form of leishmaniasis
that has the most substantial geographical overlap with HIV
and typically occurs as an opportunistic infection among
HIV-infected individuals with CD4 cell counts < 200 cells/
 
µ
 
L (64). This overlap is predominantly in southern Europe
and the horn of Africa but expansion of the HIV epidemic
in India is also likely to result in an increasing number of
co-infected individuals there. In both HIV-infected and
non-infected patients, large numbers of parasites multiply
within phagocytic mononuclear cells and induce a type 2
cytokine response and hypergammaglobulinaemia (65). T cell
proliferation and IFN-
 
γ
 
 production on stimulation with
leishmania antigen 
 
in vitro
 
 are typically deficient (66).
Many patients with VL have received ART in southern
Europe (67) and yet the number of suspected cases of IRD is
very few. It is notable that all six of the possible cases describe
the unmasking of subclinical infection following initiation
of ART, whereas none of the reports describe clinical deterio-
ration of pre-existing VL (Table 1). Two reports of IRD
associated with 
 
L. infantum
 
 VL in southern France describe
Table 1 Reported cases of immune reconstitution disease associated with parasitic infections
Organism
No. of 
cases Clinical manifestation
Baseline CD4 
cell count/µL
Presentation or 
deterioration Reference
Protozoa
Leishmania infantum 2 Visceral leishmaniasis 186, 15 Presentation Berry, 2004 (68)
Leishmania spp. 
(unspecified)
1 Visceral leishmaniasis – Presentation Albrecht, 1998 (69)
3 Visceral leishmaniasis 94, 39, 30 Presentation Jimenez-Exposito, 1999 (70)
Leishmania braziliensis 1 Cutaneous + mucosal leishmaniasis 38 Presentation Posada-Vergara, 2005 (74)
1 Cutaneous + mucosal leishmaniasis 23 Deterioration Posada-Vergara, 2005 (74)
Leishmania major 1 Uveitis 4 Presentation Blanche, 2002 (77)
Leishmania infantum 1 Post kala azar dermal leishmaniasis 35 Presentation Ridolfo, 2000 (76)
Leishmania donovani 
(presumed)
1 Post kala azar dermal leishmaniasis 150 Presentation Gilad, 2001 (75)
Toxoplasma gondii 1 Cerebral toxoplasmosis 83 Presentation Tsambiras, 2005 (86)
1 Cerebral toxoplasmosis – – Jevtovic, 2001 (85)
Helminths
Schistosoma mansoni 1 Eosinophilia 170 Presentation Fernando, 2002 (83)
1 Eosinophilic enteritis 170 Presentation de Silva, 2006 (84)
Strongyloides stercoralis 1 Fever, eosinophilia and hepatitis 32 Presentation Kim, 2004 (81)
1 Disseminated strongyloidiasis 135 Presentation Lanzafame, 2005 (82)
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asymptomatic patients who developed fever and hepato-
splenomegaly due to VL within the first 2 weeks of initiating
ART (68). Another report describes a patient who had not
been to a leishmaniasis-endemic area for 8 years and who,
following commencement of ART, soon developed fever and
thrombocytopenia due to VL (69). A further report describes
three patients in Spain who had an excellent virological response
to ART and yet developed fever and hepatosplenomegaly
during the initial months of ART (70). However, an important
study by de la Rosa 
 
et al
 
. suggests that this phenomenon is
uncommon (71). They described a series of 11 patients with
documented untreated subclinical VL who commenced ART;
none developed clinical VL during follow-up (71), suggesting
that the risk of development of VL-associated IRD among
such patients is low.
Two factors are leading to increased overlap of New World
leishmaniasis and HIV infections in South America: a rising
prevalence of leishmaniasis in urban areas as well as expansion
of the HIV epidemic into rural areas where leishmaniasis is
more common. Cutaneous, mucosal and post kala azar
dermal leishmaniasis (PKDL) are associated with an intense
granulomatous response, causing tissue pathology via a CD4
cell-dependent process (72,73). From a mechanistic viewpoint,
one might therefore expect that IRD would be more commonly
associated with tegumentary forms of disease rather than VL.
However, as yet reports of the former are few.
Two cases of IRD associated with cutaneous and mucosal
leishmaniasis have been reported from Brazil (Table 1) (74).
One patient, who had left an area endemic for leishmaniasis
15 years earlier, developed progressive cutaneous papules,
plaques and ulcers and also ulceration of the oronasopharyn-
geal mucosa after initiating ART. The second HIV-infected
patient presented with multiple cutaneous leishmaniasis lesions,
which deteriorated markedly 1 month after starting ART and
which were also accompanied by development of oronaso-
pharyngeal lesions. Diagnoses of disease due to 
 
Leishmania
braziliensis
 
 were established in both patients and both
responded well to treatment with either amphotericin B or
pentavalent antimony (74).
Two cases of PKDL presenting as IRD have been reported
from Israel (75) and Italy (76). An Ethiopian immigrant to
Israel who had been treated for VL some years earlier developed
the typical cutaneous lesions of PKDL over the face and
torso 2 weeks after initiating ART (75). The diagnosis was
histologically confirmed. The other case was an HIV-infected
patient who was initially treated for VL and then developed
PKDL on her lower limbs 6 months after commencing ART
(76). However, a diagnosis of IRD in this latter case cannot be
strongly justified and the presentation may simply represent
the normal presentation of PKDL.
A further patient with diffuse cutaneous leishmaniasis in
France treated successfully with amphotericin B developed
severe bilateral granulomatous anterior uveitis 4 months after
starting ART (77). Treatment with liposomal amphotericin
B and interferon-
 
γ
 
 (IFN-
 
γ
 
) failed to control the disease and
one eye had to be enucleated. Histological examination revealed
florid inflammation and the presence of  amastigotes. A
further similar case of fulminant ocular leishmaniasis due to
 
Leishmania donovani
 
 during ART has been reported from the
Netherlands (78). Histological examination of the enucleated
eye revealed massive granulomatous infiltrates throughout
the eye but the distinction between active infection and IRD
was unclear.
 
Strongyloidiasis
 
The lack of an association between HIV-related immuno-
deficiency and risk of disseminated strongyloidiasis has been
intriguing (79). A possible explanation for this is suggested by
data reported by Viney 
 
et al
 
., who demonstrated that progres-
sive HIV-associated CD4 lymphocytopenia was associated
with diminishing likelihood of larval maturation within the
gut. Decreased larval maturation would diminish the risk
of autoinfection – a process required in the development of
hyperinfection (80). However, two cases of possible IRD
involving disseminated strongyloidiasis have now been reported,
representing a new and unexpected interaction (81,82). Both
were in immigrants from low-income to high-income countries
and presented within the first weeks of ART. The first case
developed fever, eosinophilia and hepatitis (81); the second
patient presented with gastrointestinal symptoms and pruritis,
and investigations revealed pulmonary radiographic infiltrates
and eosinophilia (82). Numerous larvae of 
 
Strongyloides
stercoralis
 
 were found in stool specimens from both patients
and both responded well to antihelminthic treatment. Both
cases were temporally related to the commencement of ART.
It is not clear whether these cases arose due to the triggering
of immune responses to pre-existing disseminated infection
in these patients or whether immune recovery facilitated
dissemination of strongyloidiasis. Of note, the first case had
recently received corticosteroids as a component of treatment
for cerebral toxoplasmosis and this would have served as
a potent stimulus for dissemination of the strongyloides
infection prior to starting ART.
 
Schistosomiasis
 
Two cases of schistosomiasis-associated IRD have been reported
(Table 1) (83,84). The first report describes an African immi-
grant to the UK who was found to be HIV-infected and to
have hepatosplenomegaly. The baseline eosinophil count was
normal but this increased 1 month after initiating ART and
peaked at 1·5 
 
×
 
 10
 
9
 
 cells/L after 4 months of treatment. The
hepatosplenomegaly was proven by biopsy to be due to
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Schistosoma mansoni
 
 infection and the patient was treated
with praziquantel, leading to a reduction in eosinophil count.
No clinical manifestations accompanied the eosinophilia and
so this might be better termed an immune reconstitution
‘phenomenon’ rather than ‘disease’. The second report described
a South African man who emigrated to the UK and 14 years
later commenced ART (84). Treatment was stopped and
reinitiated on five occasions due to development of vomiting,
diarrhoea and abdominal pain. Symptoms developed within
the first few weeks of treatment on each occasion. Colonos-
copy revealed patchy inflammation of the large bowel and
mucosal biopsies showed florid eosinophilic granulomatous
inflammation associated with both viable and dead eggs of
 
S. mansoni.
 
 No comment was made on whether the episodes
were associated with peripheral blood eosinophilia. Subsequent
treatment for schistosomiasis led to resolution of symptoms.
Disease associated with schistosomiasis is mediated by
eosinophilic granulomatous inflammation associated with ova.
As with the cases of strongyloides-associated IRD, enhance-
ment of T helper type 2 responses may have exacerbated
eosinophilic inflammation in both of these cases. If schistosoma
eggs antigens were responsible for triggering the immune-
mediated inflammation within the intestinal wall in the case
described by de Silva 
 
et al
 
. (84), it is intriguing that symptoms
were resolved following praziquantel treatment, which would
not have affected the existing egg antigen burden within the
intestinal mucosa.
Large numbers of patients have received ART in east Africa
where the prevalence of schistosomiasis is high and yet no
reports of schistosomiasis-associated IRD have emerged
from the region. Awareness of this potential complication of
ART may lead to recognition of further cases.
 
Other parasites
 
Just two cases of suspected IRD associated with toxoplasma
encephalitis have been reported in published literature. In
one case no clinical details were given (85). In the other, an
HIV-infected patient with a nadir CD4 cell count of 83 cells/
 
µ
 
L presented with a focal seizure after 3 weeks of ART (86).
This was diagnosed as cerebral toxoplasmosis on the basis
of positive serology, multiple ring-enhancing intracerebral
lesions on a magnetic resonance imaging scan and a positive
response to treatment for toxoplasmosis. Toxoplasmosis is a
common end-stage opportunistic infection in industrialized
countries for which ART is often initiated fairly early. The
fact that more cases have not been reported casts some doubt
on whether this infection may be associated with IRD.
There are no reports in the literature of IRD associated
with helminthic or protozoal infections other than those
described above. However, an important question is whether
malaria may be associated with IRD. Although large
numbers of individuals have received ART in sub-Saharan
African countries where 
 
Plasmodium falciparum
 
 malaria is
hyperendemic, no cases of malaria-associated IRD have been
reported. The likeliest manifestation, however, might be very
non-specific such as development of fever; it seems unlikely
that severe manifestations would arise.
 
CONCLUSIONS
 
IRD associated with infections has emerged as an important
cause of morbidity complicating the initial months of ART.
As access to ART is scaled up in many low-income countries,
the extent to which IRD will contribute to morbidity and
mortality in treatment programmes has yet to be determined.
However, as patients typically present to ART services with
marked lymphocytopenia and frequent co-infections, IRD
is likely to be common. Most IRD results from dysregulated
augmentation of cell-mediated immune responses to myco-
bacterial, chronic viral and invasive fungal infections. How-
ever, the spectrum of infections recognized to be associated
with IRD now encompasses a number of parasitic diseases,
including leishmaniasis (visceral, cutaneous, mucosal and
PKDL), schistosomiasis and strongyloidiasis. No studies have
yet examined the mechanisms of IRD associated with helminth
infections, but these may be due to augmentation of appro-
priate type 2 immune responses. More research is needed to
increase our understanding of these emerging phenomena.
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